CTOR
Citius Oncology, Inc.
There isn't enough reported data to score CTOR yet.
CTOR Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
CTOR's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
CTOR PE Valuation
CTOR has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 2.6x next year's earnings.
CTOR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Strong growth | |
| -- | |
| Limited | |
| High |
Analysts expect CTOR to return to profit, with revenue growing.
CTOR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.20 | — |
| Q2 2026 | -$0.47 | -$0.09 |
CTOR lost $0.47 per share over the past year, a bigger loss than the year before.
CTOR Quarterly Revenue
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -584% | N/A |
| Q1 2026 | -1716% | N/A |
| Q4 2025 | -133% | N/A |
CTOR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2024 | $900.3K | +$1M |
| Q2 2024 | -$366.1K | -$265.9K |
| Q1 2024 | -$191.7K | -$22.9K |
CTOR has burned cash in almost every quarter: −$13M over the past year, against −$890,045 the year before.
CTOR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +7.9% | +7.9M shares |
| 1 year | +51% | +36.3M shares |
CTOR has 108M diluted shares, up 51% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2024 | — |
CTOR Net Leverage
CTOR's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
CTOR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 38.7 | Neutral |
| Stochastic | 5.0 | Oversold |
CTOR's weekly RSI is 39 (neutral) and its Stochastic is 5 (oversold).
CTOR PE vs Healthcare Sector
| Metric | CTOR | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
CTOR has no meaningful PE right now: it lost money over the past year.
CTOR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.72 | 28% below |
| 20 week MA | $0.75 | 31% below |
| 50 week MA | $0.86 | 40% below |
| 100 week MA | $1.19 | 56% below |
| 200 week MA | $5.30 | 90% below |
CTOR is in a downtrend: it's below all five of its weekly moving averages, and 90% below its 200-week average.
CTOR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2022 | $10.1 | $10.1 | +0.3% |
| 2023 | $10.1 | $10.9 | +8% |
| 2024 | $10.9 | $1.04 | -90% |
| 2025 | $1.04 | $1.13 | +8.7% |
| 2026 YTD | $1.13 | $0.52 | -54% |
CTOR is down 54% so far in 2026, after finishing higher in three of the previous four years.